Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cancer Metastasis Rev. 2018 Dec;37(4):733–748. doi: 10.1007/s10555-018-9728-y

Table 3.

Ongoing clinical trials of TRAIL-based therapies and ONC201

Therapeutic agents In combination with Trial type and tumor Reference
ABBV-621 Solid tumor/Hematologic malignancies NCT03082209
DS8273 Solid tumor NCT02076451
ONC201 Glioma NCT03134131
ONC201 Glioblastoma NCT02525692
ONC201 Glioma NCT03295396
ONC201 NHL NCT02420795
ONC201 Leukemias NCT02392572
ONC201 Myeloma NCT02863991
ONC201 Solid tumor/Myeloma NCT02609230
ONC201 Solid tumor NCT02324621
ONC201 Solid tumor NCT02250781
ONC201 Neuroendocrine tumor NCT03034200
ONC201 Breast cancer/Endometrial carcinoma NCT03394027
ONC201 Endometrial cancer NCT03099499

Abbreviations: CPT, Circularly permuted TRAIL; NR, not reported; MTD, maximum tolerated dose; ORR, objective response rate; DLT, dose limiting toxicity; TNBC, triple-negative breast cancer; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; CR, complete response; PR, partial response; SD, stable disease.